| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
| ln Vitro |
BNP, or natriuretic peptide, lowers blood pressure and ventricular fibrosis to counteract cardiac stress. The 45-residue amino-truncated version of native rat BNP is known as rBNP (1-32) [1]. The brain contains three natriuretic peptides that help regulate body fluid homeostasis: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides are concentrated in the anteroventral region of the third ventricle. Through their receptors NPR-A and NPR-B, ANP(1-28), BNP(1-32), and CNP(1-32) contribute to the regulation of salt and water balance in the mammalian brain [2].
|
|---|---|
| ln Vivo |
In conscious spontaneously hypertensive rats (SHR) and conscious cynomolgus monkeys treated with vehicle or selective neutral endopeptidase, the antihypertensive, natriuretic, and cyclic GMP effects of several brain natriuretic peptides (BNP) were evaluate. The atrial natriuretic peptide (ANP) 99-126 inhibitor SQ 28603 was used to compare the responses. The natriuretic and circulatory GMP responses to 3 nmol/kg iv rat BNP (1-32) in conscious SHR were considerably enhanced at 100 mumol/kg iv 28,603 Sq.ft. and were greater than rat ANP 99-126 larger than pig BNP-26. Neither human BNP-32 nor vehicle or SQ 28,603 were effective in treating SHR. On the other hand, 3 nmol/kg iv higher Mouse BNP (1-32) lowers mean arterial pressure without affecting renal function, while 1 nmol/kg iv human BNP (1-32) stimulates the kidneys and inhibits responses in conscious monkeys with effects greater than or comparable to those triggered by human ANP 99-126 [3].
|
| References |
[1]. Dickey DM, et al. Human B-type natriuretic peptide is not degraded by meprin A. Biochem Pharmacol. 2010 Oct 1;80(7):1007-11.
[2]. Wellard J, et al. Natriuretic peptides, but not nitric oxide donors, elevate levels of cytosolic guanosine 3',5'-cyclic monophosphate in ependymal cells ex vivo. Neurosci Lett. 2006 Jan 16;392(3):187-92. [3]. Seymour AA, et al. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther. 1992 Jul;262(1):60-70. |
| Molecular Formula |
C146H239N47O44S3
|
|---|---|
| Molecular Weight |
3452.94335999998
|
| CAS # |
133448-20-1
|
| Related CAS # |
Brain Natriuretic Peptide (1-32), rat acetate
|
| SMILES |
CC[C@@H]([C@H]1C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)=O)CC(O)=O)=O)CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CC(N)=O)=O)CO)=O)CCCCN)=O)CCSC)=O)C)=O)CC3=CN=CN3)=O)CO)=O)CO)=O)CO)=O)C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)CCCNC(N)=N)=O)CC(O)=O)=O)[C@H](CC)C)=O)CCCCN)=O)CCC(N)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)C(C)C)=O)C)=O)=O)C
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2896 mL | 1.4480 mL | 2.8961 mL | |
| 5 mM | 0.0579 mL | 0.2896 mL | 0.5792 mL | |
| 10 mM | 0.0290 mL | 0.1448 mL | 0.2896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
